The review found no eligible studies for this question.
The review found no eligible studies for this question.
Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate leads to higher physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 compared with methotrexate monotherapy (high certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in no radiographic progression in total Genant‐modified Sharp score… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).
It is very uncertain whether weekly paclitaxel changes overall survival compared with three‐weekly paclitaxel (very low certainty).
175 mg/m2 paclitaxel showed no clear difference in overall survival compared with 250 mg/m2 paclitaxel (low certainty).
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate compared with 250 mg/m2 paclitaxel (very low certainty).
175 mg/m2 paclitaxel may leads to lower response rate ‐ platinum‐sensitive compared with 250 mg/m2 paclitaxel (low certainty).
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).